An Orthotopic Mouse Model of Ovarian Cancer using Human Stroma to Promote Metastasis

被引:7
作者
Atiya, Huda, I [1 ]
Orellana, Taylor J. [2 ]
Wield, Alyssa [2 ]
Frisbie, Leonard [1 ]
Coffman, Lan G. [1 ,2 ]
机构
[1] Univ Pittsburgh, Hillman Canc Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Div Gynecol Oncol, Dept Obstet Gynecol & Reprod Sci, Magee Womens Hosp,Med Ctr, Pittsburgh, PA 15213 USA
来源
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS | 2021年 / 169期
关键词
D O I
10.3791/62382
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Ovarian cancer is characterized by early, diffuse metastasis with 70% of women having metastatic disease at the time of diagnosis. While elegant transgenic mouse models of ovarian cancer exist, these mice are expensive and take a long time to develop tumors. Intraperitoneal injection xenograft models lack human stroma and do not accurately model ovarian cancer metastasis. Even patient derived xenografts (PDX) do not fully recapitulate the human stromal microenvironment as serial PDX passages demonstrate significant loss of human stroma. The ability to easily model human ovarian cancer within a physiologically relevant stromal microenvironment is an unmet need. Here, the protocol presents an orthotopic ovarian cancer mouse model using human ovarian cancer cells combined with patient-derived carcinoma-associated mesenchymal stem cells (CA-MSCs). CA-MSCs are stromal progenitor cells, which drive the formation of the stromal microenvironment and support ovarian cancer growth and metastasis. This model develops early and diffuses metastasis mimicking clinical presentation. In this model, luciferase expressing ovarian cancer cells are mixed in a 1:1 ratio with CA-MSCs and injected into the ovarian bursa of NSG mice. Tumor growth and metastasis are followed serially over time using bioluminescence imaging. The resulting tumors grow aggressively and form abdominal metastases by 14 days post injection. Mice experienced significant decreases in body weight as a marker of systemic illness and increased disease burden. By day 30 post injection, mice met endpoint criteria of >10% body weight loss and necropsy confirmed intra-abdominal metastasis in 100% of mice and 60%-80% lung and parenchymal liver metastasis. Collectively, orthotopic engraftment of ovarian cancer cells and stroma cells generates tumors that closely mimic the early and diffuse metastatic behavior of human ovarian cancer. Furthermore, this model provides a tool to study the role of ovarian cancer cell: stroma cell interactions in metastatic progression.
引用
收藏
页数:11
相关论文
共 18 条
[1]  
American Cancer Society, 2020, K S F C
[2]   Mesenchymal Stem Cells in the Tumor Microenvironment [J].
Atiya, Huda ;
Frisbie, Leonard ;
Pressimone, Catherine ;
Coffman, Lan .
TUMOR MICROENVIRONMENT: NON-HEMATOPOIETIC CELLS, 2020, 1234 :31-42
[3]   Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma [J].
Coffman, Lan G. ;
Pearson, Alexander T. ;
Frisbie, Leonard G. ;
Freeman, Zachary ;
Christie, Elizabeth ;
Bowtell, David D. ;
Buckanovich, Ronald J. .
STEM CELLS, 2019, 37 (02) :257-269
[4]   Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop [J].
Coffman, Lan G. ;
Choi, Yun-Jung ;
McLean, Karen ;
Allen, Benjamin L. ;
di Magliano, Marina Pasca ;
Buckanovich, Ronald J. .
ONCOTARGET, 2016, 7 (06) :6916-6932
[5]  
Connolly Denise C, 2009, Curr Protoc Pharmacol, V45
[6]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[7]   Epigenomic Reprogramming toward Mesenchymal-Epithelial Transition in Ovarian-Cancer-Associated Mesenchymal Stem Cells Drives Metastasis [J].
Fan, Huihui ;
Atiya, Huda, I ;
Wang, Yeh ;
Pisanic, Thomas R. ;
Wang, Tza-Huei ;
Shih, Ie-Ming ;
Foy, Kelly K. ;
Frisbie, Leonard ;
Buckanovich, Ronald J. ;
Chomiak, Alison A. ;
Tiedemann, Rochelle L. ;
Rothbart, Scott B. ;
Chandler, Chelsea ;
Shen, Hui ;
Coffman, Lan G. .
CELL REPORTS, 2020, 33 (10)
[8]  
Ghoneum Alia, 2018, Oncotarget, V9, P22832, DOI 10.18632/oncotarget.25126
[9]   Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer [J].
Konecny, Gottfried E. ;
Wang, Chen ;
Hamidi, Habib ;
Winterhoff, Boris ;
Kalli, Kimberly R. ;
Dering, Judy ;
Ginther, Charles ;
Chen, Hsiao-Wang ;
Dowdy, Sean ;
Cliby, William ;
Gostout, Bobbie ;
Podratz, Karl C. ;
Keeney, Gary ;
Wang, He-Jing ;
Hartmann, Lynn C. ;
Slamon, Dennis J. ;
Goode, Ellen L. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (10)
[10]   The latest animal models of ovarian cancer for novel drug discovery [J].
Magnotti, Elizabeth ;
Marasco, Wayne A. .
EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (03) :249-257